Skip to content

Cerevel Therapeutics

Recent events

Recent events tied to this brand in public sources.

Back to profile3 entries

  1. 2023

    AbbVie announces acquisition of Cerevel Therapeutics

    AbbVie announced it will acquire Cerevel Therapeutics for $45 per share in cash, valuing the drugmaker at about $8.7 billion. The transaction is subject to regulatory approvals, Cerevel shareholder approval and other customary closing conditions.

  2. 2023

    Cerevel announces Ron Renaud as incoming CEO

    Cerevel Therapeutics announced Ron Renaud’s appointment as president and CEO, effective June 12, 2023; Tony Coles will continue as board chairperson.

  3. 2020

    Cerevel Therapeutics begins trading on Nasdaq

    Cerevel Therapeutics began trading on the Nasdaq on October 28, 2020, after its business combination with Arya Sciences Acquisition Corp II. The article reports net proceeds of about $440 million from the transaction.